Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer

Trial Profile

Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2018

At a glance

  • Drugs Rebastinib (Primary) ; Eribulin; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Mar 2018 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
    • 22 Mar 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
    • 02 Jun 2017 Trial design presented at 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top